ತಲೆ ಮತ್ತು ಕುತ್ತಿಗೆ ಕ್ಯಾನ್ಸರ್
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
ಎಲ್ಲಿಗೆ ಹೋಗಬೇಕು
ಈ ಟ್ರಯಲ್ಗಾಗಿ ಭಾರತದಾದ್ಯಂತ 6 ಆಸ್ಪತ್ರೆಗಳು ರೋಗಿಗಳನ್ನು ಸೇರಿಸಿಕೊಳ್ಳುತ್ತಿವೆ.
ರಿಜಿಸ್ಟ್ರಿ ಸಾರಾಂಶ (ತಾಂತ್ರಿಕ)
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
Sponsor: ಜಾನ್ಸೆನ್ ರಿಸರ್ಚ್ ಅಂಡ್ ಡೆವಲಪ್ಮೆಂಟ್, LLC
NCT07276399 on ClinicalTrials.gov
Last updated on the registry 25 Sep 2026 · read by us 20 Oct 2026